BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23867310)

  • 1. Impact of sunitinib on human thyroid cancer cells.
    Grosse J; Warnke E; Pohl F; Magnusson NE; Wehland M; Infanger M; Eilles C; Grimm D
    Cell Physiol Biochem; 2013; 32(1):154-70. PubMed ID: 23867310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of apoptosis in irradiated and sunitinib-treated follicular thyroid cancer cells.
    Grosse J; Warnke E; Wehland M; Pietsch J; Pohl F; Wise P; Magnusson NE; Eilles C; Grimm D
    Apoptosis; 2014 Mar; 19(3):480-90. PubMed ID: 24213562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1.
    Di Desidero T; Fioravanti A; Orlandi P; Canu B; Giannini R; Borrelli N; Man S; Xu P; Fontanini G; Basolo F; Kerbel RS; Francia G; Danesi R; Bocci G
    J Clin Endocrinol Metab; 2013 Sep; 98(9):E1465-73. PubMed ID: 23969186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
    Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
    J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
    Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
    J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models.
    Broutin S; Ameur N; Lacroix L; Robert T; Petit B; Oumata N; Talbot M; Caillou B; Schlumberger M; Dupuy C; Bidart JM
    Clin Cancer Res; 2011 Apr; 17(7):2044-54. PubMed ID: 21325074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib for the treatment of thyroid cancer.
    Gómez-Sáez JM
    Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sunitinib exerts only limited effects on the proliferation and differentiation of anaplastic thyroid cancer cells.
    D'Agostino M; Voce P; Celano M; Sponziello M; Moretti S; Maggisano V; Verrienti A; Durante C; Filetti S; Puxeddu E; Russo D
    Thyroid; 2012 Feb; 22(2):138-44. PubMed ID: 22191389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
    Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
    Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
    Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
    Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
    Lin CI; Whang EE; Lorch JH; Ruan DT
    Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
    Fiorio Pla A; Brossa A; Bernardini M; Genova T; Grolez G; Villers A; Leroy X; Prevarskaya N; Gkika D; Bussolati B
    BMC Cancer; 2014 Dec; 14():939. PubMed ID: 25494980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
    Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
    Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
    Leung HW; Chan AL
    Clin Ther; 2011 Jun; 33(6):708-16. PubMed ID: 21704235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
    Krusch M; Salih J; Schlicke M; Baessler T; Kampa KM; Mayer F; Salih HR
    J Immunol; 2009 Dec; 183(12):8286-94. PubMed ID: 20007592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
    Miyazaki A; Miyake H; Fujisawa M
    Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
    Sulkes A
    Isr Med Assoc J; 2010 Oct; 12(10):628-32. PubMed ID: 21090521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic cushing in a patient with medullary thyroid carcinoma: hypercortisolism control and tumor reduction with Sunitinib.
    Marques P; Vieira Mda S; Bugalho MJ
    Endocrine; 2015 May; 49(1):290-2. PubMed ID: 25022661
    [No Abstract]   [Full Text] [Related]  

  • 20. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins.
    Deprimo SE; Bello CL; Smeraglia J; Baum CM; Spinella D; Rini BI; Michaelson MD; Motzer RJ
    J Transl Med; 2007 Jul; 5():32. PubMed ID: 17605814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.